Showing results (21-30 of 65) with videos related to
Sort By:
Pageof 7
Blood|May 23, 2019
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myelomaAjai Chari, Joaquín Martinez-Lopez, María-Victoria Mateos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2010
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trialJean-Luc Harousseau, Michel Attal, Hervé Avet-Loiseau, et al.The Lancet. Haematology|December 22, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation studyPaul G Richardson, Sundar Jagannath, Philippe Moreau, et al.The New England Journal of Medicine|September 15, 2007
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosisArnaud Jaccard, Philippe Moreau, Veronique Leblond, et al.Blood|June 15, 2011
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trialsPeter M Fayers, Antonio Palumbo, Cyrille Hulin, et al.Blood|April 7, 2021
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final resultsMurielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, et al.Blood|July 5, 2019
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Maria-Victoria Mateos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trialCyrille Hulin, Thierry Facon, Philippe Rodon, et al.British Journal of Haematology|December 23, 2016
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myelomaNoopur S Raje, Philippe Moreau, Evangelos Terpos, et al.Blood|September 8, 2005
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocolPhilippe Moreau, Cyrille Hullin, Frédéric Garban, et al.Pageof 7